AbbVie Inc. (ABBV)

NYSE: ABBV · Real-Time Price · USD
229.57
+2.70 (1.19%)
At close: Oct 17, 2025, 4:00 PM EDT
229.99
+0.42 (0.18%)
After-hours: Oct 17, 2025, 7:55 PM EDT
1.19%
Market Cap405.55B
Revenue (ttm)58.33B
Net Income (ttm)3.72B
Shares Out 1.77B
EPS (ttm)2.10
PE Ratio109.31
Forward PE19.58
Dividend$6.56 (2.86%)
Ex-Dividend DateOct 15, 2025
Volume7,149,387
Open227.52
Previous Close226.87
Day's Range226.81 - 230.71
52-Week Range163.81 - 244.81
Beta0.51
AnalystsBuy
Price Target232.05 (+1.08%)
Earnings DateOct 31, 2025

About ABBV

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Sector Healthcare
Founded 2012
Employees 55,000
Stock Exchange NYSE
Ticker Symbol ABBV
Full Company Profile

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial Statements

Analyst Summary

According to 22 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $232.05, which is an increase of 1.08% from the latest price.

Price Target
$232.05
(1.08% upside)
Analyst Consensus: Buy
Stock Forecasts

News

AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition

AbbVie earns a Strong Buy rating in my book, driven by Rinvoq's label expansions and robust immunology pipeline growth. ABBV achieved FDA approval for Rinvoq in giant cell arteritis and reported stron...

5 hours ago - Seeking Alpha

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). NORT...

12 hours ago - PRNewsWire

Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending

The Investment Committee give you their top stocks to watch for the second half.

Other symbols: AMZNDDOGTSLX
4 days ago - CNBC Television

U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease

-        Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisa...

4 days ago - PRNewsWire

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie's growing ADC portfolio designed to target difficult-to-trea...

4 days ago - PRNewsWire

SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer

By the makers of BOTOX® Cosmetic (onabotulinumtoxinA), SkinMedica®'s new packaging features a refreshed logo, modernized look, and luxe copper color palette. The brand's new HA5® moisturizer is design...

8 days ago - PRNewsWire

My Top 5 Biotech Stocks Big Pharma Could Buy Next

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...

11 days ago - Seeking Alpha

AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

OnabotulinumtoxinA (BOTOX®) met the primary endpoint in the Phase 2 trial, demonstrating a statistically significant improvement from baseline in the Tremor Disability Scale-Revised (TREDS-R) total un...

11 days ago - PRNewsWire

AbbVie expects $2.7 billion R&D charge in third quarter

Drugmaker AbbVie in a regulatory filing on Friday said it expects third-quarter earnings to include a $2.7 billion charge related to in-process research and development (IPR&D) expenses.

14 days ago - Reuters

AbbVie: Wins Accumulating While We Wait For Next BD Steps

AbbVie is outperforming expectations with strong commercial results, pipeline progress, and the legal win that secured Rinvoq's long-term market exclusivity. ABBV has raised the full-year revenue guid...

14 days ago - Seeking Alpha

ABBV Stock vs. Eli Lilly & Merck

AbbVie stock (NYSE: ABBV) rallied 11% in a week, largely driven by a key development that boosted the entire sector: Pfizer's agreement to lower its drug prices for Medicaid and a White House decision...

Other symbols: LLYMRK
15 days ago - Forbes

AbbVie to Host Third-Quarter 2025 Earnings Conference Call

NORTH CHICAGO, Ill. , Oct. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2025 financial results on Friday, October 31, 2025, before the market opens.

15 days ago - PRNewsWire

Natrelle® Awarded Supplier Agreement from Vizient

This agreement grants Vizient clients enhanced access to Natrelle®, the broadest selection of breast implant options on the market. IRVINE, Calif.

16 days ago - PRNewsWire

AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.

Expansion increases biologics manufacturing for immunology and oncology medicines Milestone marks progress on AbbVie's long-term commitment to U.S. manufacturing Furthers longstanding commitment to Ab...

17 days ago - PRNewsWire

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options

– BLA based on data from the global Phase 1/2 CADENZA trial NORTH CHICAGO, Ill. , Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced submission of a new Biologics License Application (...

17 days ago - PRNewsWire

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its mult...

18 days ago - GlobeNewsWire

AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility

New state-of-the-art active pharmaceutical ingredient (API) facility will manufacture immunology, oncology and neuroscience medicines Facility expected to be fully operational and serving patients by ...

18 days ago - PRNewsWire

AbbVie to launch ovarian cancer drug in UK at the same list price as US

AbbVie said on Monday it would launch its ovarian cancer drug Elahere in the U.K. at a list price equal to that in the U.S.

18 days ago - Reuters

AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)

The list price will be consistent with the United States to reflect the value of the innovation AbbVie is committed to ensuring that developed nations fully recognize the value of our medicines in imp...

18 days ago - PRNewsWire

AbbVie For Healthy Dividend Growth

AbbVie is rated a strong buy for its strong dividend growth, robust fundamentals, and proven track record as a Dividend King. ABBV offers a compelling mix of a 3% yield and nearly 7% annual historical...

20 days ago - Seeking Alpha

Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham

CNBC's “Closing Bell Overtime” team discusses President Trump's plan to impose a 100% tariff on “all any branded or patented Pharmaceutical Product” entering the U.S. with Geoff Meacham of Citi Resear...

Other symbols: AMGNLLYMRK
21 days ago - CNBC Television

Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen

Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.

Other symbols: AMGNGILDLLYMRKMRNAPFE
21 days ago - CNBC Television

Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access

John Flavin, Portal Innovations founder and CEO, joins CNBC's 'Squawk on the Street' to discuss the Trump administration's proposed pharmaceutical tariffs, the impact on biotech startups and clinical ...

Other symbols: LLYMRKPFEBIIBBMY
21 days ago - CNBC Television

AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease

Submission supported by data from the Phase 3 TEMPO program that demonstrated symptomatic improvement across the Parkinson's disease spectrum Positive results across all three Phase 3 TEMPO trials rei...

21 days ago - PRNewsWire

AbbVie's Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists

Spherix Global Insights finds majority of specialists expect Rinvoq's uptake to accelerate, with potential implications branching to the polymyalgia rheumatica landscape. Spherix Global Insights finds...

22 days ago - GlobeNewsWire